# A Study for Aggressive Adult T-cell Leukemia-lymphoma (ATLL)

> **NCT00145002** · PHASE3 · COMPLETED · sponsor: **Japan Clinical Oncology Group** · enrollment: 130 (—)

## Conditions studied

- Adult T-cell Leukemia
- Lymphoma

## Interventions

- **DRUG:** VCAP-AMP-VECP with G-CSF and intrathecal prophylaxis
- **DRUG:** biweekly-CHOP with G-CSF and intrathecal prophylaxis

## Key facts

- **NCT ID:** NCT00145002
- **Lead sponsor:** Japan Clinical Oncology Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-08
- **Primary completion:** —
- **Final completion:** 2004-12
- **Target enrollment:** 130 (—)
- **Last updated:** 2016-09-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00145002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00145002, "A Study for Aggressive Adult T-cell Leukemia-lymphoma (ATLL)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00145002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*